Biofrontera (BFRI) Net Cash Flow (2020 - 2025)

Biofrontera's Net Cash Flow history runs 6 years deep, the most recent figure standing at $2.9 million for Q4 2025.

• On a quarterly basis, Net Cash Flow fell 3.71% year-over-year to $2.9 million in Q4 2025; TTM through Dec 2025 was -$8.1 million, a 277.59% decrease from a year earlier, with the FY2025 full-year figure at $448000.0, down 90.11% from the prior year.
• Net Cash Flow grew to $2.9 million in Q4 2025 per BFRI's latest filing, from -$3.8 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $22.8 million in Q4 2021 and bottomed at -$10.4 million in Q4 2022.
• The 5-year median for Net Cash Flow is -$1.8 million (2023), against an average of -$1.0 million.
• Across the five-year window, Net Cash Flow soared 526.23% in 2021 and tumbled 12443.9% in 2023, its largest moves.
• Year by year, Net Cash Flow stood at $22.8 million in 2021, then sank by 145.51% to -$10.4 million in 2022, then soared by 79.98% to -$2.1 million in 2023, then surged by 246.66% to $3.0 million in 2024, then decreased by 3.71% to $2.9 million in 2025.
• Per Business Quant, the three latest BFRI Net Cash Flow figures stand at $2.9 million (Q4 2025), -$3.8 million (Q3 2025), and -$3.1 million (Q2 2025).